Department of Clinical Laboratory Diagnosis, School of Clinical Medicine, Jiamusi University, Jiamusi, China.
Central Laboratory, Longgang District Maternal and Child Health Hospital, Shenzhen, China.
Medicine (Baltimore). 2021 Nov 5;100(44):e27718. doi: 10.1097/MD.0000000000027718.
This retrospective study aimed to explore the effect of enteral nutrition (EN) on immune and inflammatory factors after liver cancer surgery (LCS).It was retrospectively conducted on enrolled LCS patients between January 2017 and May 2020. The medical records of 528 patient case records were collected and reviewed. After selection, a total of 80 eligible patient case records were finally included. All those patients received routine diet, and they were allocated to a treatment group (n = 40) and a control group (n = 40). In addition, patients in the treatment group also received EN. The primary outcomes were immune factors (CD4+, CD8+, CD4+/CD8+) and inflammatory factors (interleukin-1, interleukin-6, and tumor necrosis factor-α). The secondary outcomes were postoperative hospital stay (day), time to first bowel sounds (hour), time to first flatus (day), time to first defecation (day), and complications.There were not significant differences in CD4+/CD8+ (P = .34), postoperative hospital stay (P = .39), and time to first bowel sounds (P = .17) between 2 groups. However, there were significant differences in CD4+ (P < .01), CD8+ (P < .01), interleukin-1 (P < .01), interleukin-6 (P < .01), tumor necrosis factor-α (P < .01), time to first flatus (P < .01), and time to first defecation (P < .01) between 2 groups. As for complications, there were not significant differences between 2 groups (P > .05).The results of this study found that EN may benefit for patients after LCS during the recovery period. Future high quality prospective studies are needed to warrant the present conclusion.
这项回顾性研究旨在探讨肝癌手术后(LCS)肠内营养(EN)对免疫和炎症因子的影响。该研究回顾性纳入了 2017 年 1 月至 2020 年 5 月期间的 LCS 患者。收集并回顾了 528 例患者的病历记录,经过筛选,最终纳入了 80 例符合条件的患者病历记录。所有患者均接受常规饮食,分为治疗组(n=40)和对照组(n=40)。此外,治疗组患者还接受了 EN。主要结局指标为免疫因子(CD4+、CD8+、CD4+/CD8+)和炎症因子(白细胞介素-1、白细胞介素-6 和肿瘤坏死因子-α)。次要结局指标为术后住院时间(天)、首次肠鸣音时间(小时)、首次排气时间(天)、首次排便时间(天)和并发症。两组间 CD4+/CD8+(P=0.34)、术后住院时间(P=0.39)和首次肠鸣音时间(P=0.17)无显著差异。然而,两组间 CD4+(P<0.01)、CD8+(P<0.01)、白细胞介素-1(P<0.01)、白细胞介素-6(P<0.01)、肿瘤坏死因子-α(P<0.01)、首次排气时间(P<0.01)和首次排便时间(P<0.01)均有显著差异。至于并发症,两组间无显著差异(P>0.05)。本研究结果发现,EN 可能有利于 LCS 术后患者的恢复。需要未来开展高质量的前瞻性研究来验证本研究结论。